Ingen, Jakko vanAliberti, StefanoAndrejak, ClaireChalmers, James D.Codecasa, Luigi R.Daley, Charles L.Hasegawa, NaokiGriffith, David E.Hoefsloot, WouterHuitt, GwenJarand, JulieJhun, Byung WooLoebinger, Michael R.Marras, Theodore K.Morimoto, KozoPolverino, EvaRingshausen, Felix C.Santín Cerezales, MiguelThomson, RachelWagner, DirkWallace, Richard J.Winthrop, Kevin L.Yim, Jae-joon2021-11-042021-11-042020-09-101537-6591https://hdl.handle.net/2445/181039Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset. These opinions can provide assistance in individual patient management decisions.4 p.application/pdfengcc by-nc-nd (c) Ingen, Jakko van et al, 2020http://creativecommons.org/licenses/by-nc-nd/3.0/es/Malalties del pulmóAntibiòticsPulmonary diseasesAntibioticsinfo:eu-repo/semantics/article2021-11-04info:eu-repo/semantics/openAccess32910814